- funded by IMI-JU
- 01 March 2011 - 31 August 2016
- 11 EFPIA members
- 10 Academia and 5 SME's
- Total cost € 23,032,609
Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe’s European Federation of Pharmaceutical Industries and Associations Members. F Mentré, M Chenel, E Comets, J Grevel, A Hooker, MO Karlsson, M Lavielle and I Gueorguieva. CPT: Pharmacometrics & Systems Pharmacology 2013, 2, e46 Abstract Methods and software tools for optimal design in nonlinear mixed effect models, based on the Fisher information matrix, have been developed for a decade. Academic groups regularly proposed new versions. Present tools do not incorporate adaptive designs for these models although prior information is needed and adaptive designs are increasingly used in drug development. We conducted a study among drug companies of the Drug and Disease Model Resources consortium to identify current practices and expectations.
Andrew Hooker Uppsala Universitet |
|
Emmanuelle Comets UPD |
|
France Mentré UPD |
|
Marc Lavielle Inria |
|
Mats Karlsson Uppsala Universitet |
Ivelina Gueorguieva Eli Lilly |
|
Marylore Chenel Institut de Recherches Internationales Servier |